BAMATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BAMATE (BAMATE).
The mechanism of action of BAMATE is not well established; it is thought to involve inhibition of monoamine oxidase (MAO) with preferential inhibition of MAO-B at low doses, leading to increased concentrations of dopamine and other biogenic amines in the brain.
| Metabolism | Hepatic metabolism via monoamine oxidase (MAO) enzymes; also undergoes acetylation and conjugation. Specific CYP450 enzymes not well characterized. |
| Excretion | BAMATE is primarily excreted renally as unchanged drug (approximately 60-70%) and as glucuronide conjugates (20-30%). Fecal elimination accounts for less than 10%. |
| Half-life | Terminal elimination half-life is 2-4 hours in healthy adults. This short half-life necessitates frequent dosing to maintain therapeutic levels. |
| Protein binding | Approximately 15-20% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is approximately 0.5-1.0 L/kg, indicating distribution into total body water and some extravascular compartments. |
| Bioavailability | Oral bioavailability is complete (100%) as BAMATE is well absorbed from the gastrointestinal tract with minimal first-pass metabolism. |
| Onset of Action | Following oral administration, clinical effects (anxiolytic and muscle relaxant) typically appear within 30-60 minutes. |
| Duration of Action | Duration of action is 4-6 hours after a single oral dose. Due to its short half-life, multiple daily doses are required for sustained effect. |
400 mg orally twice daily
| Dosage form | TABLET |
| Renal impairment | eGFR 30-89 mL/min: no adjustment; eGFR <30 mL/min: not recommended |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated |
| Pediatric use | Not recommended for use in children under 18 years of age |
| Geriatric use | Initiate at 200 mg orally twice daily; titrate slowly based on tolerance |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BAMATE (BAMATE).
| Breastfeeding | BAMATE is excreted into breast milk; M/P ratio unknown. Potential for sedation and withdrawal symptoms in breastfed infants. Use with caution, monitor infant for lethargy, poor feeding, and respiratory depression. Consider temporary discontinuation of breastfeeding during therapy. |
| Teratogenic Risk | First trimester: No adequate human data; animal studies show no teratogenic effects at up to 10 times the human dose. Second and third trimesters: Increased risk of neonatal withdrawal syndrome (hypertonia, tremors, irritability) with chronic use near term. Avoid use in first trimester unless clearly needed. |
■ FDA Black Box Warning
There is no FDA-issued black box warning for BAMATE.
| Serious Effects |
["Hypersensitivity to the drug or any of its components","Concurrent use of other MAOIs or within 14 days of discontinuation","Concurrent use of SSRIs, SNRIs, TCAs, or other serotonergic agents","Pheochromocytoma","Uncontrolled hypertension","Advanced renal or hepatic disease"]
| Precautions | ["Hypertensive crisis if used with tyramine-rich foods or sympathomimetic drugs","Risk of serotonin syndrome if combined with serotonergic drugs","May cause orthostatic hypotension","May exacerbate psychotic symptoms in susceptible individuals","Caution in patients with hepatic or renal impairment"] |
| Food/Dietary | Avoid alcohol. No specific food interactions; however, grapefruit juice may increase meprobamate levels (theoretical). Take with or without food. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and signs of CNS depression. Fetal ultrasound to monitor growth and amniotic fluid volume. Neonatal monitoring for withdrawal symptoms (e.g., Finnegan scale) for at least 48 hours after delivery if used near term. |
| Fertility Effects | Animal studies show no adverse effects on fertility at therapeutic doses. Human data lacking; theoretical risk of hormonal disruption but not established. No evidence of impaired fertility in clinical use. |
| Clinical Pearls | Bamate is a brand name for meprobamate, a carbamate derivative anxiolytic. Monitor for CNS depression, respiratory depression, and hypotension, especially in elderly or those with hepatic impairment. Abrupt discontinuation may cause seizures. Use with caution in patients with history of substance abuse. |
| Patient Advice | Take exactly as prescribed; do not increase dose or frequency without consulting your doctor. · Avoid alcohol and other CNS depressants (e.g., opioids, benzodiazepines) due to risk of severe sedation and respiratory depression. · Do not drive or operate heavy machinery until you know how this medication affects you. · Do not stop taking abruptly; gradual dose reduction is necessary to avoid withdrawal symptoms (anxiety, insomnia, seizures). · Inform your doctor if you have a history of drug abuse, depression, or suicidal thoughts. · Report any signs of allergic reaction (rash, hives, difficulty breathing) or unusual bleeding/bruising. |